Bayer Partnering 2005-2013

Keywords : Therapy

The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service. This report provides all the information you require to better understand Bayer and its partnering interests and activities over the past seven years. One of the key aspects of partnering is finding those companies that are potential partners for ...

More »

Please note: this report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible.

The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service.

This report provides all the information you require to better understand Bayer and its partnering interests and activities over the past seven years.

One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives.

The initial chapters of this report provide an orientation of bigpharma’s dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partnering and M&A 2005 to present date based on headline value.

Chapter 4 provides details on how to approach bigpharma companies with partnering opportunities whilst chapter 5 lists forthcoming partnering events and conferences where bigpharma companies will be present to discuss opportunities face to face.

The main body of the report is provided in chapter 6. A profile of the company provides everything required to assess the suitability of a company as a prospective partner. This includes a company overview, partnering interests, partnering activity according to deal type, industry sector, phase of development, and therapy area. The profile also includes in-depth contact information for individuals within the business development function.

The deals are listed by deal type, stage of development and therapy focus, allowing easy access to deals and alliances of interest. Every deal record links to an online, live version of the deal record at the Current Agreements deals and alliances database. Where available, deal records also include the contract document as disclosed at the SEC.

One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

Understanding the flexibility of prospective partners’ negiotated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

In addition, contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each parties ability to derive value from the deal.

In summary, the report provides the user with the tools to make successful contact with the right partners effectively and efficiently.


Partnering Agreements with Bayer report provides the user with the following key benefits:

Detailed company profile of the company
Partnering interests and therapy focus revealed
Partnering activity since 2005 – number of deals per year
Partnering activity for 2005-present
Activity by deal type
Activity by phase of development
Activity by therapeutic area
List of recent partner companies
Detailed listing of all partnering deals since 2005
Comprehensive access to actual contracts entered into by the company and its partners*
Insight into the terms included in a partnering agreement
Understand the key deal terms the company has agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
*Subject to being published via regulatory requirements of the Securities Exchange Commission.

Therapy Industry

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Biopharma top 50 and dealmaking activity

2.1 Biopharma partnering activity
2.2 Biopharma M&A activity

Chapter 3 – Top bigpharma deals by value

3.1 Bigpharma M&A
3.2 Bigpharma partnering

Chapter 4 – Submitting Opportunities to Prospective Partners

4.1 How to submit an opportunity
4.2 Opportunity submission template
4.3 Sending emails
4.4 Face to face at partnering events
4.5 Online submission forms

Chapter 5 – Forthcoming partnering events

Chapter 6 – Company Profile

6.1 How to use company profiles
6.2 Field definitions
6.3 Company profile
Partnering deals directory (2005-present) - by industry sector
Bigpharma
Pharmaceutical
Biotech
Diagnostic
Drug delivery
Government
Medical device
Consumer health
Specialty pharma
Generic pharma
Agricultural
Animal health
Academic
Non-profit
Research tools
Services

Partnering deals directory (2005-present) - By deal type
Asset purchase
Co-Development
Co-Market
Co-Promotion
Collaborative R&D
Contract service
Development
Distribution
Evaluation
Joint venture
Licensing
Manufacture
Marketing
Promotion
Research
Royalty financing
Supply

Partnering deals directory (2005-present) – M&A

Partnering deals directory (2005-present) - By stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation

Partnering deals directory (2005-present) - By therapy area
Hospital care
Cardiovascular
Central nervous system
Cosmetic
Dental
Dermatology
Gastrointestinal
Genetic disorders
Genitourinary
Hemotology
Immunology
Infectives
Inflammatory
Metabolic
Musculoskeletal
Oncology
Ophthalmics
Respiratory
Sensory organ

About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports
Order Form – Partnering Agreements Company Profiles

TABLE OF FIGURES

Figure 1: Bigpharma partnering activity – top 50 by pharma sales
Figure 2: Bigpharma M&A activity – top 50 by pharma sales
Figure 3: Leading M&A deals involving bigpharma by value, 2005-2011
Figure 4: Leading partnering deals by value, 2005-2011
Figure 5: Typical partnering opportunity submission template
Figure 6: Company profile template and definitions used in report
Figure 7: Dealmaking frequency 2005-2011
Figure 8: Current partner companies (2005-present)
Figure 9: Partnering deals by type (2005-present)
Figure 10: Recent deals (2005-present) by industry sector
Figure 11: Recent deals (2005-present) by deal type
Figure 12: Recent deals (2005-present) by stage of development
Figure 13: Recent deals (2005-present) by therapy area